Michael Bolton opens up about brain cancer diagnosis
Singer Michael Bolton is opening up about his battle with brain cancer.
In an interview with People Magazine, his family said Bolton started having unusual symptoms before his diagnosis in 2023.
In addition to headaches and nausea, they said that one night while bowling, he was completely unaware that he kept bowling out of turn. Later that night, he fell out of his chair.
They then insisted he see a doctor, and that's when an MRI confirmed the presence of a brain tumor.
Bolton, 72, was diagnosed with glioblastoma and underwent emergency surgery in December 2023, where doctors removed the tumor. He underwent a second brain surgery in January 2024 because of an infection, the outlet said.
In October, he completed his chemotherapy and radiation treatments. He's had to undergo scans every two months to make sure the tumor hasn't returned. His latest scan was in April and it was 'clear.'
The singer-songwriter told the magazine that his short-term memory, speech and mobility have been affected by the treatments.
'You're reaching into your resources and your resolve in a way that you never would have thought,' Bolton said. 'Succumbing to the challenge is not an option. You're really quickly drawn into a duel. I guess that's the way you find out what you're made of.'
'Glioblastoma (also known as Glioblastoma multiforme or GBM) is the most aggressive type of tumor that arises in the brain. It is one of the most lethal forms of brain cancer,' according to the Glioblastoma Foundation.
'Whenever you find yourself in any kind of challenging position, just to know that you're not alone going through it is a big deal,' he continued. 'It actually helps people to know. It reminds them that they're not alone.'
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
26 minutes ago
- Yahoo
Biking might help lower risk of dementia
Want to reduce your risk of dementia and Alzheimer's disease? Get on your bike and ride, a new study recommends. Biking regularly for transportation appears to lower risk of dementia by 19% and Alzheimer's by 22%, according to results published Tuesday in JAMA Network Open. The results also suggest that cycling might even help increase the size of a brain region important for memory, researchers noted. "Cycling is a moderate- to high-intensity workout, and also requires balance," said Dr. Liron Sinvani, director of geriatric services at Northwell Health in Manhasset, N.Y., who reviewed the findings. "It requires more complex brain function than walking, which is why maybe it was a better reducer of dementia risk." "It's not about just doing exercise and making that part of your routine, but thinking about the way you live your life," she added in a news release. "So instead of having to drive somewhere, taking that bike and using active travel modes to get around as part of your lifestyle becomes very important." For the study, researchers analyzed data on nearly 480,000 people participating in the UK Biobank, a long-term health study of people living in England, Scotland and Wales. As part of the study, participants noted the forms of transport they used most often to get about, not including travel to and from work. During an average follow-up of 13 years, more than 8,800 participants developed dementia and nearly 4,000 developed Alzheimer's. Results showed a lower risk for dementia and Alzheimer's among those who cycled or included cycling among other forms of travel like walking, driving or using public transportation. "Our findings suggest that promoting active travel strategies, particularly cycling, may be associated with lower dementia risk among middle-aged and older adults, which carries substantial public health benefits by encouraging accessible, sustainable practices for cognitive health preservation," concluded the research team led by Liangkai Chen, an associate professor at Tongji Medical College at the Huazhong University of Science and Technology in Wuhan, China. MRI brain scans showed that cycling also was associated with a larger hippocampus, a part of the brain involved in memory formation and learning, researchers noted. However, cycling's benefits appeared to extend mostly to people without a genetic risk for Alzheimer's, results showed. People without the APOE E4 genetic variant had a 26% lower risk of dementia and 25% lower risk of Alzheimer's. Results were not statistically significant among APOE E4 carriers, but indicated less protection from cycling. Interestingly, the results also indicate that driving offered some protection against dementia compared to taking the bus or subway. "Even when using inactive travel like car or public transportation, it seemed like driving had a little bit better impact [on brain health] than public transportation," Sinvani said in the news release. However, researchers noted that this observational study could not draw a direct cause-and-effect link between cycling and healthy brain aging. "What I tell my patients and family and friends whenever they ask me what they can do to reduce their risk of dementia, is whatever gets you outside doing stuff is what you should be doing," she said. "I think we see that it's not just the physical activity, but it's also in the balance, and it really engages different parts of your brain." If you're able to get on a bike, Sinvani said, do that. If you're aren't, use your feet. "I think if it's, 'should I walk or take a bike?' I would say take a bike, but if it's 'should I walk or just stay home?' I would say definitely walk," she said. More information The U.S. Centers for Disease Control and Prevention has more on how physical activity boosts brain health. Copyright © 2025 HealthDay. All rights reserved.
Yahoo
37 minutes ago
- Yahoo
Merck's Cholesterol Medication Achieves Primary Endpoint in Two Trials
Merck & Co., Inc. (NYSE:MRK) is one of the best Dow stocks to invest in. On June 9, the company announced that its drug, enlicitide decanoate, achieved its primary goal of lowering a specific type of cholesterol in two late-stage clinical trials. A close-up of a person's hand holding a bottle of pharmaceuticals. The medication is being studied as a potential treatment for hyperlipidemia, a condition marked by high levels of fat in the bloodstream. According to the company, enlicitide led to significant reductions in LDL-C, or "bad" cholesterol, in patients with existing heart disease or those at risk of developing it. Merck & Co., Inc. (NYSE:MRK) is a global healthcare organization focused on providing innovative health solutions through its medicines, vaccines, biologic therapies, and animal health products. The stock has surged by over 1% in the past month. While we acknowledge the potential of MRK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure. None.
Yahoo
an hour ago
- Yahoo
SRx Health Solutions Announces Management and Board Changes
TAMPA, Fla., June 11, 2025 (GLOBE NEWSWIRE) -- SRx Health Solutions, Inc. (NYSE American: SRXH) (the 'Company'), a leading global health and wellness company, today announced the following management team and Board of Directors changes. Lionel Conacher, current Board member, has been appointed as Chairman of the Board, Adesh Vora, current Executive Chairman, will remain on Board and be appointed Chief Executive Officer, Kent Cunningham, current Chief Executive Officer, will assume role as President, and Nina Martinez has been appointed Chief Financial Officer. Adesh Vora, Chief Executive Officer of SRx Health Solutions, stated, 'We are grateful to our Board and senior management for their efforts in strengthening our team structure and enhancing corporate governance. These improvements align with our renewed vision for SRx Health's long-term strategic growth. Looking ahead, our core focus will be on supporting patients managing chronic and rare diseases, infusion services, clinical trials, and patient support programs to make healthcare simpler for our customers. At the same time, we will continue to build on our values—partnering with patients, pharmaceutical manufacturers, and prescriber relations.' About SRx Health Solutions, Inc. SRx Health Solutions Inc. is an integrated Canadian healthcare services provider that operates within the specialty healthcare industry. The SRx network extends across all ten Canadian provinces, making it one of the most accessible providers of comprehensive, integrated, and customized specialty healthcare services in the country. SRx combines years of industry knowledge, technology, and patient-centric focus to create strategies and solutions that consistently exceed client expectations and drive critical patient care initiatives aimed to improve the wellness of Canadians. For more information on SRx Health Solutions Inc., please visit Forward Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words 'believe,' 'may,' 'estimate,' 'continue,' 'anticipate,' 'intend,' 'should,' 'plan,' 'could,' 'target,' 'potential,' 'is likely,' 'will,' 'expect' and similar expressions, as they relate to us, are intended to identify forward-looking statements. The Company has based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. Some or all of the results anticipated by these forward-looking statements may not be achieved. Further information on the Company's risk factors is contained in our filings with the SEC. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law. Company Contact:SRx Health Solutions, A. Vora, Chief Executive Officer Investor Contact:KCSA Strategic CommunicationsValter Pinto, Managing DirectorT: 212-896-1254Valter@
